摘要
目的检测肺癌患者化疗前后外周血淋巴细胞(PBL)中多药耐药基因(mdr1)表达水平,探讨其与化疗疗效的相互关系。方法分别于化疗开始前及化疗周期结束后第3周收集肺癌患者(n=32)外周血标本。采集标本的同时行胸片或胸部CT扫描,并计算肿瘤最大径及垂直径的乘积。运用实时荧光定量逆转录-聚合酶链反应(fqRT-PCR)法检测PBL中mdr1基因的表达。结果与化疗前相比,化疗后PBL中mdr1 mRNA水平上升显著[(3.881 8±0.828 0)与(4.3166±0.923 1),t=-4.207,P=0.000]。化疗前后外周血mdr1 mRNA水平变化与肿瘤大小改变间亦存在负相关关系(r=-0.389,P=0.028)。化疗前小细胞肺癌(SCLC)与非小细胞肺癌(NSCLC)患者PBL中mdr1转录本水平间存在显著性差异,SCLC明显低于NSCLC[(2.831 4±0.398 4)与(4.231 9±0.603 4),t=6.101,P=0.000]。结论NSCLC及SCLC在化疗耐药机制上可能存在差异性。检测患者化疗前后PBL中mdr1 mRNA水平对判定化疗疗效有一定的指导意义,可在一定程度上指导化疗方案的修订。
Objective To detect muhidrug resistance gene （mdr1） transcription in peripheral blood lymphocyte （PBL） before and after chemotherapy and to determine its correlation with chemotherapeutic effect. Methods The peripheral blood sample was taken from each lung cancer patients （n = 32） before chemotherapy and at 3rd week after chemotherapy and subjected to fluorescent quantitative real-time RT-PCR. Simultaneously the tumor size was determined by chest X-ray or CT. Results The mdr1 mRNA level in PBL after chemotherapy increased significantly as compared with that before chemotherapy [ （4.316 6 ±0. 923 1 ） vs （3. 881 8 ± 0. 828 0）, t = - 4.207, P = 0. 000 ]. There was an negative correlation between mdr1 mRNA level and the tumor size （r = -0.389, P =0. 028）. The level of mdr1 transcription in SCLC patients was significantly less than that of NSCLC patients before chemotherapy [ （2. 831 4 ±0.398 4） vs （4. 231 9 ±0. 603 4）, t =6. 101, P = 0. 000 ]. Conclusion In terms of an anticancer drug resistant mechanism, there could be a difference between NSCLC and SCLC. Longitudinal study of mdr1 level in PBL is valuable for evaluating the treatment response.
出处
《第三军医大学学报》
CAS
CSCD
北大核心
2006年第19期1979-1982,共4页
Journal of Third Military Medical University
基金
重庆市卫生局科研基金资助项目(00-2004)~~
